DE602005016917D1 - Fgf-21-fusionsproteine - Google Patents

Fgf-21-fusionsproteine

Info

Publication number
DE602005016917D1
DE602005016917D1 DE602005016917T DE602005016917T DE602005016917D1 DE 602005016917 D1 DE602005016917 D1 DE 602005016917D1 DE 602005016917 T DE602005016917 T DE 602005016917T DE 602005016917 T DE602005016917 T DE 602005016917T DE 602005016917 D1 DE602005016917 D1 DE 602005016917D1
Authority
DE
Germany
Prior art keywords
fgf
fusion protein
fusion proteins
specific
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005016917T
Other languages
English (en)
Inventor
Wolfgang Glaesner
Rohn Lee Millican
Yu Tian
Sheng-Hung Tschang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602005016917D1 publication Critical patent/DE602005016917D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
DE602005016917T 2004-05-13 2005-05-02 Fgf-21-fusionsproteine Active DE602005016917D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57009804P 2004-05-13 2004-05-13
PCT/US2005/015111 WO2005113606A2 (en) 2004-05-13 2005-05-02 Fgf-21 fusion proteins

Publications (1)

Publication Number Publication Date
DE602005016917D1 true DE602005016917D1 (de) 2009-11-12

Family

ID=34967856

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016917T Active DE602005016917D1 (de) 2004-05-13 2005-05-02 Fgf-21-fusionsproteine

Country Status (12)

Country Link
US (1) US7576190B2 (de)
EP (2) EP2194064A1 (de)
JP (1) JP2008506635A (de)
AT (1) ATE444306T1 (de)
CA (1) CA2565300A1 (de)
DE (1) DE602005016917D1 (de)
DK (1) DK1751184T3 (de)
ES (1) ES2332100T3 (de)
PL (1) PL1751184T3 (de)
PT (1) PT1751184E (de)
SI (1) SI1751184T1 (de)
WO (1) WO2005113606A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP2412816B1 (de) 2004-07-26 2014-12-03 Pfenex Inc. Verfahren zur verbesserten Proteinexpression durch Strain-Engineering
EP1789442B1 (de) * 2004-09-02 2009-09-30 Eli Lilly And Company Muteine des fibroblasten-wachstumsfaktors 21
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CN102625811B (zh) * 2008-10-10 2016-09-21 安姆根有限公司 Fgf21突变体及其用途
EP2389190B1 (de) * 2009-01-23 2018-09-19 Novo Nordisk A/S Fgf21-derivate mit albuminbinder a-b-c-d-e- und deren verwendung
EP2427207B1 (de) 2009-05-05 2017-08-16 Amgen, Inc Fgf21-mutanten und ihre verwendungen
EA021425B1 (ru) 2009-05-05 2015-06-30 Амген Инк. Мутанты fgf21 и их применение
MX2011013903A (es) 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
RU2573896C2 (ru) * 2009-10-15 2016-01-27 Дженентек, Инк. Химерные факторы роста фибробластов с измененной рецепторной специфичностью
MX2012006397A (es) * 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2460527A1 (de) * 2010-01-21 2012-06-06 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
WO2011120013A2 (en) 2010-03-26 2011-09-29 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
US20130116171A1 (en) 2010-04-16 2013-05-09 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
JP2013533227A (ja) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
SG190082A1 (en) * 2010-11-05 2013-06-28 Covx Technologies Ireland Ltd Anti-diabetic compounds
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US8980266B2 (en) 2011-06-28 2015-03-17 Inhibrx, Llc Serpin fusion polypeptides and methods of use thereof
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2548570A1 (de) 2011-07-19 2013-01-23 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
WO2013093720A2 (en) 2011-12-22 2013-06-27 Pfizer Inc. Anti-diabetic compounds
CN108103069B (zh) 2012-02-15 2021-08-10 诺和诺德股份有限公司 结合并阻断髓样细胞表达的触发受体-1 (trem-1)的抗体
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
PL2814842T3 (pl) 2012-02-15 2018-12-31 Novo Nordisk A/S Przeciwciała wiążące białko 1 rozpoznające peptydoglikan
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
CA2871656A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
AU2013277051B2 (en) * 2012-06-22 2018-06-07 King's College London Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN109793893B (zh) 2012-09-07 2023-05-26 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
MX2016005101A (es) 2013-10-21 2017-01-09 Salk Inst For Biological Studi Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA2935378C (en) 2013-12-24 2023-04-18 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
MX2016016310A (es) 2014-06-11 2017-10-20 A Green Kathy Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
KR20170020383A (ko) * 2014-06-24 2017-02-22 노보 노르디스크 에이/에스 Mic-1 융합 단백질 및 그것의 사용
TN2017000008A1 (en) 2014-07-17 2018-07-04 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
PT3412302T (pt) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Polipéptidos de fgf-21 modificados e utilizações dos mesmos
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
PT3236991T (pt) 2014-12-23 2019-09-06 Novo Nordisk As Derivados de fgf21 e usos dos mesmos
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
TWI756204B (zh) 2016-02-12 2022-03-01 比利時商楊森製藥公司 抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
SG11201808633RA (en) 2016-04-15 2018-10-30 Immunext Inc Anti-human vista antibodies and use thereof
EP3502143A4 (de) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. Linker-peptid zur konstruktion von fusionsprotein
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
BR112020004136A2 (pt) 2017-09-08 2020-09-08 Bristol-Myers Squibb Company fator de crescimento de fibroblastos modificado 21 (fgf-21) para uso nos métodos de tratamento de esteato-hepatite não alcoólica (nash)
CN111727055A (zh) * 2018-02-06 2020-09-29 温哥华生物技术有限公司 GHR-106单克隆抗体作为GnRH拮抗剂的用途
CN116098989A (zh) 2018-02-08 2023-05-12 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
JOP20200240A1 (ar) 2018-04-02 2020-09-27 Bristol Myers Squibb Co أجسام مضادة ضد- trem-1 واستخداماتها
BR112020026512A2 (pt) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company Formulações de fgf-21
CN111195349B (zh) * 2018-11-16 2023-02-24 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干粉制剂
CN114853908A (zh) 2019-05-16 2022-08-05 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
TW202140074A (zh) 2020-01-08 2021-11-01 美商必治妥美雅史谷比公司 Fgf-21結合物調配物
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US528582A (en) 1894-11-06 Can-opener
US606830A (en) 1898-07-05 Insulator
US606805A (en) 1898-07-05 Can-opener
US635882A (en) 1898-11-02 1899-10-31 Henry Torrance Jr Refrigerating system.
EP0770135A1 (de) 1994-07-29 1997-05-02 Smithkline Beecham Plc Neuartige verbindungen
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1232264B1 (de) 1999-11-18 2009-10-21 Novartis Vaccines and Diagnostics, Inc. Menschliches fgf-21 gen und genexpressionsprodukte
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU5056501A (en) 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
PT1355942E (pt) 2000-12-07 2008-11-21 Lilly Co Eli Proteínas de fusão de glp-1
BRPI0411112A (pt) 2003-06-12 2006-07-18 Lilly Co Eli proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga

Also Published As

Publication number Publication date
DK1751184T3 (da) 2009-11-23
ATE444306T1 (de) 2009-10-15
EP2194064A1 (de) 2010-06-09
EP1751184A2 (de) 2007-02-14
US7576190B2 (en) 2009-08-18
ES2332100T3 (es) 2010-01-26
CA2565300A1 (en) 2005-12-01
SI1751184T1 (sl) 2010-01-29
JP2008506635A (ja) 2008-03-06
WO2005113606A2 (en) 2005-12-01
US20070237768A1 (en) 2007-10-11
EP1751184B1 (de) 2009-09-30
PT1751184E (pt) 2009-11-10
WO2005113606A3 (en) 2006-05-04
PL1751184T3 (pl) 2010-02-26

Similar Documents

Publication Publication Date Title
DE602005016917D1 (de) Fgf-21-fusionsproteine
WO2005091944A3 (en) Glycol linked fgf-21 compounds
ATE517120T1 (de) Igf-1 fusion polypeptide und deren therapeutische verwendung
NO2017028I1 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
DE60135581D1 (de) Glp-1 fusion proteine
EP1845105A4 (de) Modifizierte exendine und anwendungen davon
ATE482724T1 (de) Pegylierte glp-1-verbindungen
ATE396738T1 (de) Verwendung von glp-2-peptiden
DE60238541D1 (de) Modifizierte transferrin-fusionsproteine
ATE473011T1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy- terminalen domänen
EA200702408A1 (ru) Аналоги глюкагонподобного пептида-2 (glp-2)
HRP20050354B1 (de)
ITMI20030372A1 (it) Perfluoropolieteri lineari aventi migliorata stabilita' termoossidativa.
ATE452646T1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
BRPI0414008B8 (pt) compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula
DE502005002646D1 (de) Heuwerbungsmaschine
DK1539221T3 (da) Transferrin-fusionsproteinbiblioteker
ATE502047T1 (de) T-helper antigenic determinant (thd) peptide
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
DE69801520T2 (de) Insulinbindendes Polypeptid
RU2004131483A (ru) Натуральная композиция на основе меда
ES1044950U (es) Brazo perfeccionado, para tumbonas, hamacas de jardin y/o similares.
ES1055592U (es) Lienzo para cuadros artisticos perfeccionado.
ES1051818Y (es) Fuente.
ES1049463U (es) Somier de lamas para canape.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN